Start-up Australia invests in bone-building tech
Monday, 04 April, 2005
Venture capital fund Start-up Australia Ventures has invested AUD$3 million in junior biotech Caldeon, which is collaborating with the University of Western Australia to optimise osteoporosis drug leads which could reduce bone loss.
"This discovery is a genuine first in the bone metabolism field. This is the first agent to be discovered that specifically stimulates and protects the specialised cells responsible for forming bone," said Prof Ming-Hao Zheng, a co-discoverer of the compounds, along with Dr Jiake Xu and Dr Tony Phan.
Start-up Australia has $55 million under management. Its previous investmest include Alchemia, EvoGenix, Mimetica, Promics, Protagonist, Cortical, Iliad Chemicals and Replikun Biotech
The funding is to be supplied in milestone-based tranches.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
